New vaccine trial targets deadliest brain cancer
NCT ID NCT05283109
First seen Nov 01, 2025 · Last updated May 01, 2026 · Updated 30 times
Summary
This early-stage trial tests a vaccine made from small protein pieces (peptides) designed to train the immune system to attack glioblastoma, an aggressive brain cancer. It includes 24 adults with newly diagnosed, untreated tumors. The main goal is to check safety and find the right dose, while also measuring immune responses.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOMA, MALIGNANT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The Preston Robert Tisch Brain Tumor Center at Duke University
Durham, North Carolina, 27710, United States
Conditions
Explore the condition pages connected to this study.